Navigation Links
Jefferson researchers find nanoparticle shows promise in reducing radiation side effects

A gene responsible for the production of a protein called vasostatin may prove a promising new way of treating pancreatic cancer, suggests research published ahead of print in Gut.

Pancreatic cancer is the fifth leading cause of cancer deaths in the developed world, and is extremely difficult to treat. Only 3% of affected patients are still alive five years after diagnosis, a survival rate that has remained static for the past three decades.

Currently, the only viable treatment is surgery. Radiotherapy and chemotherapy have little impact on the disease.

The research team investigated the potential of the protein vasostatin to suppress the development of new blood vessels and pancreatic tumour cells both in test tubes and in mice with pancreatic cancer.

'Solid' tumours, such as pancreatic cancer, are heavily dependent on a rich blood supply to enable them to grow rapidly and spread throughout the body. This process is known as angiogenesis.

The protein gene was incorporated into a virus (adenovirus), so that it would be able to penetrate the cells, acting as a vector.

The test tube experiments showed that 72 hours after infection with the genetically modified virus, vasostatin was clearly active in the tissue. Tumour growth in the mice was also curbed, and when compared with mice which had not been infected with the virus, the difference between the two groups was highly significant.

The researchers then looked more closely at the pancreatic cells and the cell linings of the blood vessels (vascular endothelial cells).

They found that although vasostatin seemed to have little impact on the pancreatic cells, it blocked the formation of new blood vessels, effectively cutting off the supply of nutrients to the malignant cells. This effect was seen in both the test tube and animal experiments.

This type of gene therapy "may be a potent strategy to treat many malignant tumours, including pancreatic can cer, and represents a promising therapeutic option for malignancy with a poor prognosis," conclude the authors.


'"/>

Source:Thomas Jefferson University


Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
3. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
4. Jefferson researchers building a better rabies vaccine
5. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
6. Immune cell communication key to hunting viruses, Jefferson immunologists show
7. Jefferson researchers uncover new way nature turns genes on and off
8. Jefferson scientists find aging gene also protects against prostate cancer development
9. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
10. Jefferson researchers discovery may change thinking on how viruses invade the brain
11. Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology: